Precision tools for the reading room.
158 interactive calculators and classification systems — each cross-checked against the published literature and linked to its primary sources. Search above or pick a system below.
How to search: type a full name, a common abbreviation, or the organ/system involved — e.g. "tirads", "prostate", "stroke", or "tici" all find the right tool. Press / or ⌘K to jump to the search box from anywhere.
Body & Abdominal Imaging
Hepatobiliary, genitourinary, pancreatic and solid-organ tools.
Quantifies signal drop of an adrenal lesion from in-phase to opposed-phase gradient-echo MRI. Values above validated thresholds indicate intracellular lipid and support a lipid-rich adenoma.
Computes absolute and relative percentage washout of an adrenal nodule on multiphase CT. Adenomas typically enhance briskly and wash out rapidly, meeting the 60% absolute or 40% relative washout thresholds.
Names pancreatic and peripancreatic collections correctly per the Revised Atlanta Classification and scores radiologic severity of acute pancreatitis with the Modified CT Severity Index (Mortele).
Estimates total thyroid volume from three orthogonal measurements of each lobe using the standard ellipsoid formula or the Brunn (WHO) correction factor.
Scores a thyroid nodule from five ultrasound feature categories and maps the total to ACR TI-RADS levels TR1-TR5 with size-based FNA and follow-up recommendations.
Assigns colonic (C0-C4) and extracolonic (E0-E4) categories for CT colonography per the ACR C-RADS 2023 update, with the corresponding management recommendations.
Cardiothoracic Imaging
Coronary CTA, lung nodule and lung cancer screening systems.
Standardized coronary CTA reporting: assigns a stenosis category (0, 1, 2, 3, 4A, 4B, 5, or N), an overall plaque-burden grade (P1–P4), and modifiers (N, HRP, I, S, G, E), then pairs the composite code with management suggestions for stable or acute chest pain.
Follow-up recommendations for pulmonary nodules found incidentally on CT in adults 35 years or older, combining nodule number, composition (solid, part-solid, or pure ground-glass), mean size, and clinical risk of malignancy.
ACR Lung-RADS v2022 categories (0, 1, 2, 3, 4A, 4B) for lung cancer screening LDCT, covering solid, part-solid, and ground-glass nodules as well as juxtapleural nodules, airway nodules, and atypical pulmonary cysts, with size, growth, and stepped-management rules.
Estimates the probability that a pulmonary nodule found on a baseline screening low-dose CT is malignant, using the McWilliams (PanCan/Brock University) logistic models. Implements all four published variants (parsimonious and full, each with or without spiculation).
Estimates the pre-test probability that a radiologically indeterminate solitary pulmonary nodule is malignant from age, smoking, remote cancer history, nodule diameter, spiculation and upper-lobe location (Swensen 1997).
Quantifies pulmonary arterial clot burden in acute PE as a percentage obstruction index. Each thrombus scores points equal to the number of segmental branches distal to it, weighted 1 for partial and 2 for total occlusion; the index is Σ(n·d)/40 × 100%.
Emergency & Trauma
Solid-organ injury grading and acute care scoring.
Grades renal trauma on contrast CT according to the 2018 revision of the AAST organ injury scale, including the vascular-injury upgrade rules.
Grades hepatic trauma on CT with the 2018 revision of the AAST organ injury scale, including vascular-injury and active-bleeding criteria.
Grades splenic trauma on CT with the 2018 revision of the AAST organ injury scale, in which any splenic vascular injury is at least grade IV.
Decides whether a non-contrast head CT is warranted after a minor head injury (Glasgow Coma Scale 13-15) using five high-risk and two medium-risk criteria. Any single criterion present means the rule recommends imaging.
Identifies blunt-trauma patients who can forgo cervical spine imaging. Imaging is considered unnecessary only when all five low-risk criteria are absent: no midline tenderness, no focal deficit, normal alertness, no intoxication, and no distracting injury.
Stratifies children under 18 with minor head trauma (GCS 14-15) into CT recommended, observation versus CT, or very low risk with no CT, using separate predictor trees for children younger than 2 years and children 2 years or older.
Neuroradiology & Spine
Stroke, vascular, skull base and spinal classification tools.
Scores early ischemic change in the ten MCA-territory regions on non-contrast CT; the score is 10 minus the number of abnormal regions.
Computes percent ICA stenosis by the NASCET method (residual lumen vs normal distal ICA) and the ECST method (residual lumen vs estimated bulb diameter).
Estimates parenchymal hematoma volume on CT with the ABC/2 method (ellipsoid hematomas) or ABC/3 variant (irregular, separated, or multinodular hematomas).
Classifies thoracolumbar spine injuries into morphology types A0–A4, B1–B3 and C together with neurologic status (N0–N4/NX) and the M1/M2 modifiers, and derives the Thoracolumbar AOSpine Injury Score (TL AOSIS) that feeds the published surgical algorithm.
Grades parasellar extension of a pituitary adenoma on coronal MRI from its relationship to the medial tangent, intercarotid line, and lateral tangent of the cavernous carotid artery, using the revised 0–4 scale with the 3A/3B subdivision.
ACR NI-RADS risk-stratifies post-treatment head and neck surveillance imaging: the primary site and the neck nodes are each categorized 0–4 for suspicion of recurrence, with linked management from routine surveillance to biopsy or treatment.
Musculoskeletal Imaging
Bone lesion reporting and follow-up frameworks.
ACR Bone-RADS (2023) scores six radiographic features of a potentially neoplastic bone lesion — margination, periosteal reaction, endosteal scalloping, pathological fracture, extra-osseous soft-tissue mass, and known primary cancer — and maps the point total to risk categories 1–4 with management suggestions.
Classifies pediatric growth-plate (physeal) fractures into types I through V by the path of the fracture line relative to the metaphysis, physis, and epiphysis. Higher types carry progressively greater risk of growth arrest and more often need surgery.
Estimates remaining skeletal growth from ossification and fusion of the iliac apophysis on a frontal pelvis or scoliosis radiograph. Both grading traditions are supported: the US system (stages 0-5, dividing the crest into quarters) and the French system (stages 0-4, dividing it into thirds).
Grades intracapsular femoral neck fractures I through IV on an AP radiograph by completeness and displacement, using the alignment of femoral head and acetabular trabeculae. The key clinical dichotomy is nondisplaced (I-II) versus displaced (III-IV).
Classifies proximal humerus fractures by counting how many of the four anatomic segments - articular head, greater tuberosity, lesser tuberosity, and shaft - are displaced. A segment counts as displaced when it is separated by more than 1 cm or angulated more than 45 degrees.
Radiographic grading of osteoarthritis severity from 0 (none) to 4 (severe) based on osteophytes, joint-space narrowing, subchondral sclerosis, and bony deformity. Originally described for multiple joints and most often applied to the knee.
Nuclear Medicine & Theranostics
Radioligand therapy dosing and scintigraphy scoring.
Determines whether lutetium Lu-177 dotatate (Lutathera) should be continued at full activity, withheld and resumed at 3.7 GBq, or permanently discontinued, based on the type and severity of an adverse reaction.
Maps adverse reactions during lutetium Lu-177 vipivotide tetraxetan (Pluvicto) therapy to the prescribing-information actions: continue, withhold, reduce the dose once by 20% to 5.9 GBq, or permanently discontinue.
Sums MIBG-avid disease burden across nine skeletal zones plus a soft-tissue zone, each graded 0-3, to yield the Curie score (0-30) used for neuroblastoma staging, response assessment, and prognosis.
Categorizes FDG-PET treatment response (CMR, PMR, SMD or PMD) from the change in peak standardized uptake value corrected for lean body mass (SULpeak), with an optional James-formula lean body mass helper.
Scores the most intense residual FDG uptake on a lymphoma PET/CT against the mediastinal blood pool and liver (Deauville 1-5, with suffix X) and maps the score plus its change from baseline to the Lugano metabolic response category.
Assigns the lesion-level PSMA-RADS version 1.0 category for a finding on PSMA-targeted PET. Returns the official likelihood-of-malignancy wording and the recommended next step (observation, follow-up, biopsy, or treat as disease).
Vascular & Interventional
Hemodynamics, renal function and procedural risk scores.
Estimates glomerular filtration rate from serum creatinine, age, and sex using the 2021 race-free CKD-EPI creatinine equation, with KDIGO G1-G5 staging.
Computes the MELD 3.0 score from bilirubin, INR, creatinine, sodium, albumin, sex, and dialysis status, with the corresponding estimated 90-day survival; the current standard for liver transplant allocation.
Stratifies 30-day mortality risk in acute pulmonary embolism from 11 clinical variables (original PESI, classes I-V) and reports the simplified PESI alongside.
Calculates the arterial resistive index (PSV - EDV) / PSV from spectral Doppler velocities and flags elevation against the usual native-renal threshold of about 0.70.
Grades post-thrombotic syndrome after deep vein thrombosis by summing five patient-reported symptoms and six clinician-assessed signs (each 0-3), with a venous ulcer automatically signifying severe disease.
Scores seven bedside items to classify suspected pulmonary embolism as unlikely or likely (two-tier) or low/moderate/high (three-tier), directing the workup to D-dimer testing or straight to imaging.
Women's Imaging
Adnexal lesion risk stratification and obstetric biometry.
Assigns an ACR O-RADS US (v2022) category 0-5 to an ovarian or adnexal lesion from its ultrasound descriptors, returning the associated malignancy risk band and management guidance.
Estimates gestational age from crown-rump length (Robinson 1975), second-trimester biometry (Hadlock 1984 BPD/HC/AC/FL with composite averaging), or last menstrual period, and derives an estimated date of delivery (Naegele's rule).
Maps the ACR BI-RADS 5th-edition final assessment categories (0–6, including the 4A/4B/4C subdivisions) to their published malignancy-likelihood ranges and management recommendations for mammography, ultrasound, and breast MRI.
Assigns the ACR O-RADS MRI score (0–5) to a sonographically indeterminate adnexal lesion from its composition, fluid and lipid content, and the DCE time-intensity curve (or non-DCE early enhancement) of any solid tissue, with the associated malignancy PPV and management pathway.
Computes sonographic estimated fetal weight from standard biometry using the Hadlock 1985 log10 regressions (BPD/AC/FL or HC/AC/FL), and — when gestational age (24–42 weeks) is given — reports the percentage of the expected 50th-percentile weight and an approximate growth percentile from the Hadlock 1991 in-utero weight standard.
Sums the four-quadrant deepest vertical pockets into the amniotic fluid index and classifies fluid volume as oligohydramnios, normal, or polyhydramnios (with severity), cross-checked against the single deepest pocket. Both the SMFM (AFI ≥24 cm) and the traditional (AFI ≥25 cm) polyhydramnios conventions are offered as labeled options.
Oncology Response
Tumor response assessment frameworks for CT, MRI and PET.
Assigns the RECIST 1.1 overall response category (CR, PR, SD or PD) for a single follow-up time point from the change in the sum of target-lesion diameters, the non-target lesion status and the presence of new lesions.
Applies the modified RECIST criteria for hepatocellular carcinoma, in which only the arterially enhancing (viable) portion of each target lesion is measured, to categorize response as CR, PR, SD or PD.
Evaluates gastrointestinal stromal tumor response to tyrosine-kinase inhibitors using both tumor size and CT attenuation, classifying the examination as CR, PR, SD or PD by the Choi criteria.
Applies iRECIST (Seymour 2017) to solid-tumor immunotherapy assessments. Apparent progression or new lesions first score as unconfirmed progressive disease (iUPD); confirmed progressive disease (iCPD) requires repeat imaging 4-8 weeks later showing further increase in tumor burden or worsening/new lesions. New lesions are measured in a separate sum and are not added to the original target-lesion sum.
Assigns CR, PR, SD, or PD for high-grade glioma using classic RANO (Wen 2010) rules: bidimensional sum of products of perpendicular diameters (SPD) of measurable enhancing disease, plus T2/FLAIR trend, corticosteroid dose, clinical status, and new lesions. Notes how RANO 2.0 (2023) changes baseline timing, confirmation of early PD, volumetrics, and use of non-enhancing disease.